What your oncologist actually needs from a China treatment period
Targeted cancer treatment acts on particular molecular features of a tumour, and biomarker findings can help clinicians assess potential treatment options. That is the clinical logic behind the therapy, but it is not the handover document. Your oncologist needs to reconstruct what was given, why it was chosen, whether it worked, and what it cost you in side effects.
A frequent gap in a returning patient's file is not the scan report. It is the drug record. A patient may remember the brand name but not the generic name, or the starting dose but not the reductions. A receiving oncologist cannot judge tolerability or plan an alternative without the dose history and the dates it changed.
A second gap is the safety record. Targeted therapies can cause specific problems that need monitoring, and the pattern matters more than any single value. If you had a rash, diarrhoea, liver enzyme rise, blood pressure change or thyroid abnormality during treatment in China, that belongs in the file with the date and the action taken, even if it resolved.
You do not need to interpret these records. You need to collect them in a form your oncologist can read. Ask the treating hospital in China for a discharge summary, the medication administration record, and the laboratory and imaging reports from the treatment period. If the hospital provides a patient portal or app export, that is often the fastest route.
The drug and dose record: what to request and why it changes the next step
Ask the hospital for a written medication history covering the whole period, not just the last cycle. It should show the drug name, the dose, the route, the dates of each cycle, and any dose reductions or interruptions with the reason recorded. If a drug was changed, the record should show what it was changed to and when.
This matters because your oncologist's next step depends on it. A patient who stopped a drug because of a specific toxicity is in a different position from one who completed a planned course. A patient whose dose was reduced twice is different again. Without those details, the receiving clinician is working from memory and assumption.
If the hospital used a generic or locally manufactured version of a drug, ask for the generic name and the manufacturer as recorded. Do not rely on the brand name alone. If you have the original packaging or a photo of it, keep it with the records.
Ask also for the pathology and molecular testing reports that supported the choice of therapy. These are often held separately from the treatment records. Your oncologist will want to see the actual report, not a verbal summary, because the specific finding and the test method can affect how it is interpreted.
Safety events, unresolved results and the questions they raise
A safety event is any symptom, laboratory change or clinical finding that required monitoring, a dose change, a delay or additional treatment. Collect these with dates. If a scan showed a possible new finding that was not resolved before you left, include the scan report and the clinician's note about what was planned.
Unresolved results are a specific problem in cross-border handover. A test may have been ordered but the result was not back before discharge, or a follow-up scan was scheduled after your departure. Your oncologist needs to know these exist so they can decide whether to repeat them, request them from China, or manage them locally.
Do not try to resolve these questions yourself. The receiving oncologist decides whether a result is clinically significant in your case. Your role is to make sure the question is visible in the file rather than buried in a discharge summary.
If you are still in China, ask the treating team what follow-up they recommend and whether they can provide the pending results to you or to your oncologist directly. If you have already left, contact the hospital's international office or medical records department and ask what their process is for releasing records to a patient or a clinician abroad. Confirm the format, the language and whether a translation is provided.
What the receiving oncologist decides, and what you should not assume
Your oncologist decides whether the China treatment is continued, modified, stopped or replaced. They decide what monitoring is needed and what tests to order. They decide whether any part of the China record needs verification or repetition. None of that is determined by the fact that treatment happened in China.
Do not assume that a drug used in China is available, approved or funded in your home country. Do not assume that a dose used in China will be continued at the same level. Do not assume that your oncologist will accept the China molecular testing without review. These are clinical and regulatory questions for the receiving team, and the answers vary by drug, country and individual case.
It is reasonable to ask your oncologist directly: what do you need from the China records to make a decision? That question is more useful than sending everything at once. Some clinicians want the full file; others want a focused summary first and the raw reports on request.
If your oncologist asks for clarification that you cannot provide, say so. A gap in the record is better identified than filled with a guess. The treating team can then decide whether to request the information from China or proceed with what is available.
Communication, translation and who is responsible for what
The China hospital is responsible for the accuracy of the records it releases. Your oncologist is responsible for interpreting them and deciding your care. You are responsible for requesting the records, keeping them together, and passing them on. A coordination service can help with logistics, but it does not take over any of those responsibilities.
If the records are in Chinese, ask the hospital whether an English version is available. If not, a translation may be needed. A clinical translation is different from a general one: drug names, doses, units and dates must be exact. Ask the translator to keep the original terms alongside the translation where a drug or test name is ambiguous.
When you send records to your oncologist, include a short cover note with the dates of treatment, the drug names, and a list of any unresolved questions. Keep it factual. Your oncologist does not need a narrative of your experience; they need the clinical facts in order.
If your oncologist wants to speak with the treating clinician in China, ask both sides whether that is possible and what arrangements they need. Do not assume it will happen. Time zones, language and hospital policy all affect whether a direct conversation can be arranged.
Preparing the handover file: a practical checklist
A complete handover file is not a single document. It is a set of records that together answer what was given, what happened, and what remains open. The checklist below is a way to organise the request, not a universal requirement. Ask your oncologist which items they want first.
Start with the treatment summary and medication record. Add the pathology and molecular testing reports. Add the imaging reports from before, during and after treatment. Add the laboratory results that triggered any change in dose or monitoring. Add the discharge summary and any pending results. Keep a one-page timeline at the front so the oncologist can see the sequence at a glance.
If you are planning further care in China, the same file is useful in reverse. A receiving hospital in China will want to know your treatment history, your current status and what your oncologist at home has recommended. The records travel in both directions.
For general information on how targeted therapy is assessed and planned, see the ChinaSpecialistCare targeted therapy reference. It explains the assessment route; it does not replace your oncologist's review of your own records.
- Treatment summary with dates and cycles
- Medication record with drug names, doses and changes
- Pathology and molecular testing reports
- Imaging reports from before, during and after treatment
- Laboratory results linked to dose changes or safety events
- Discharge summary and pending or unresolved results
- One-page timeline at the front
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.